Is Cogent Biosciences Stock a Good Investment?
Cogent Biosciences Investment Advice | COGT |
- Examine Cogent Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Cogent Biosciences' leadership team and their track record. Good management can help Cogent Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Cogent Biosciences' business and its evolving consumer preferences.
- Compare Cogent Biosciences' performance and market position to its competitors. Analyze how Cogent Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Cogent Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Cogent Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Cogent Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Cogent Biosciences is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Cogent Biosciences Stock
Researching Cogent Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 100.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.48. Cogent Biosciences last dividend was issued on the 9th of November 2020. The entity had 1:4 split on the 9th of November 2020.
To determine if Cogent Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cogent Biosciences' research are outlined below:
| Cogent Biosciences generated a negative expected return over the last 90 days | |
| Cogent Biosciences has high historical volatility and very poor performance | |
| Net Loss for the year was (192.41 M) with loss before overhead, payroll, taxes, and interest of (121.63 M). | |
| Cogent Biosciences currently holds about 325.56 M in cash with (153.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95. | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Ferrante Karen Jean of 2513 shares of Cogent Biosciences at 8.02 subject to Rule 16b-3 |
Cogent Biosciences Quarterly Cost Of Revenue |
|
Cogent Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cogent Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cogent Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Cogent Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Cogent Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-02-26 | 2023-12-31 | -0.56 | -0.63 | -0.07 | 12 | ||
2021-11-10 | 2021-09-30 | -0.41 | -0.48 | -0.07 | 17 | ||
2021-08-16 | 2021-06-30 | -0.36 | -0.43 | -0.07 | 19 | ||
2021-05-12 | 2021-03-31 | -0.41 | -0.34 | 0.07 | 17 | ||
2024-10-31 | 2024-09-30 | -0.5664 | -0.6412 | -0.0748 | 13 | ||
2024-05-07 | 2024-03-31 | -0.52 | -0.62 | -0.1 | 19 | ||
2020-08-11 | 2020-06-30 | -0.84 | -0.96 | -0.12 | 14 | ||
2023-11-02 | 2023-09-30 | -0.5 | -0.64 | -0.14 | 28 |
Know Cogent Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cogent Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cogent Biosciences backward and forwards among themselves. Cogent Biosciences' institutional investor refers to the entity that pools money to purchase Cogent Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Adage Capital Partners Gp Llc | 2024-06-30 | 4.2 M | State Street Corp | 2024-06-30 | 3.8 M | Deerfield Management Co | 2024-09-30 | 3.7 M | Sofinnova Ventures | 2024-06-30 | 2.8 M | Geode Capital Management, Llc | 2024-09-30 | 2.3 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2 M | Saturn V Capital Management Llc | 2024-09-30 | 1.7 M | Octagon Capital Advisors Lp | 2024-09-30 | 1.3 M | Millennium Management Llc | 2024-06-30 | 1.2 M | Point72 Asset Management, L.p. | 2024-09-30 | 10.5 M | Kynam Capital Management, Lp | 2024-09-30 | 9.2 M |
Cogent Biosciences' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.06 B.Market Cap |
|
Cogent Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.61) | (0.64) | |
| Return On Capital Employed | (0.76) | (0.79) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (0.75) | (0.78) |
Determining Cogent Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Cogent Biosciences is a good buy. For example, gross profit margin measures Cogent Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cogent Biosciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Cogent Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cogent Biosciences. Check Cogent Biosciences' Beneish M Score to see the likelihood of Cogent Biosciences' management manipulating its earnings.
Evaluate Cogent Biosciences' management efficiency
Cogent Biosciences has return on total asset (ROA) of (0.4402) % which means that it has lost $0.4402 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7847) %, meaning that it created substantial loss on money invested by shareholders. Cogent Biosciences' management efficiency ratios could be used to measure how well Cogent Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.64 in 2024. Return On Capital Employed is likely to drop to -0.79 in 2024. At this time, Cogent Biosciences' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 14.4 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 21.1 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.24 | 3.07 | |
| Tangible Book Value Per Share | 3.24 | 3.07 | |
| Enterprise Value Over EBITDA | (2.11) | (2.00) | |
| Price Book Value Ratio | 1.82 | 1.23 | |
| Enterprise Value Multiple | (2.11) | (2.00) | |
| Price Fair Value | 1.82 | 1.23 | |
| Enterprise Value | 502.9 M | 528.1 M |
At Cogent Biosciences, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 0.021 |
Basic technical analysis of Cogent Stock
As of the 29th of November, Cogent Biosciences shows the Mean Deviation of 2.33, downside deviation of 4.48, and Risk Adjusted Performance of 0.0083. Cogent Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cogent Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cogent Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cogent Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cogent Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cogent Biosciences' Outstanding Corporate Bonds
Cogent Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cogent Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cogent bonds can be classified according to their maturity, which is the date when Cogent Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| CCOI 7 15 JUN 27 Corp BondUS19240CAE30 | View | |
| US19240CAC73 Corp BondUS19240CAC73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand Cogent Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Cogent Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0083 | |||
| Market Risk Adjusted Performance | 0.0032 | |||
| Mean Deviation | 2.33 | |||
| Semi Deviation | 4.31 | |||
| Downside Deviation | 4.48 | |||
| Coefficient Of Variation | 151725.42 | |||
| Standard Deviation | 3.45 | |||
| Variance | 11.9 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.14) | |||
| Total Risk Alpha | (0.53) | |||
| Sortino Ratio | (0.03) | |||
| Treynor Ratio | (0.01) | |||
| Maximum Drawdown | 21.15 | |||
| Value At Risk | (6.85) | |||
| Potential Upside | 4.79 | |||
| Downside Variance | 20.03 | |||
| Semi Variance | 18.59 | |||
| Expected Short fall | (2.08) | |||
| Skewness | (1.75) | |||
| Kurtosis | 6.04 |
| Risk Adjusted Performance | 0.0083 | |||
| Market Risk Adjusted Performance | 0.0032 | |||
| Mean Deviation | 2.33 | |||
| Semi Deviation | 4.31 | |||
| Downside Deviation | 4.48 | |||
| Coefficient Of Variation | 151725.42 | |||
| Standard Deviation | 3.45 | |||
| Variance | 11.9 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.14) | |||
| Total Risk Alpha | (0.53) | |||
| Sortino Ratio | (0.03) | |||
| Treynor Ratio | (0.01) | |||
| Maximum Drawdown | 21.15 | |||
| Value At Risk | (6.85) | |||
| Potential Upside | 4.79 | |||
| Downside Variance | 20.03 | |||
| Semi Variance | 18.59 | |||
| Expected Short fall | (2.08) | |||
| Skewness | (1.75) | |||
| Kurtosis | 6.04 |
Consider Cogent Biosciences' intraday indicators
Cogent Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cogent Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cogent Biosciences Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 13th of June 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Cogent Stock media impact
Far too much social signal, news, headlines, and media speculation about Cogent Biosciences that are available to investors today. That information is available publicly through Cogent media outlets and privately through word of mouth or via Cogent internal channels. However, regardless of the origin, that massive amount of Cogent data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cogent Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cogent Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cogent Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cogent Biosciences alpha.
Cogent Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Cogent Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cogent Biosciences Corporate Management
| Rachael MD | VP Development | Profile | |
| Sara Saltzman | VP Affairs | Profile | |
| Jessica MD | Chief Officer | Profile | |
| Brad Fell | Senior Chemistry | Profile | |
| Christi Waarich | Senior Relations | Profile | |
| Brad Barnett | Chief Officer | Profile |
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.